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Abstract
 
Leukocyte migration is a key event both in host defense against invading pathogens as well as
in inflammation. Bacteria generate chemoattractants primarily by excretion (formylated pep-
tides), complement activation (C5a), and subsequently through activation of leukocytes (e.g.,
leukotriene B4, platelet-activating factor, and interleukin 8). Here we describe a new protein
secreted by 
 
Staphylococcus aureus 
 
that specifically impairs the response of neutrophils and mono-
cytes to formylated peptides and C5a. This chemotaxis inhibitory protein of 
 
S. aureus
 
 (CHIPS)
is a 14.1-kD protein encoded on a bacteriophage and is found in 
 
 
 
60% of clinical isolates.
CHIPS reduces the neutrophil recruitment toward C5a in a mouse peritonitis model, even
though its activity is much more potent on human than on mouse cells. These findings suggest
a new immune escape mechanism of 
 
S. aureus
 
 and put forward CHIPS as a potential new anti-
inflammatory therapeutic compound.
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Introduction
 
Staphylococcus aureus
 
 is a Gram-positive pathogen and a major
cause of wound and nosocomial infections in humans causing
high morbidity and mortality (1). 
 
S. aureus
 
 produces a wide
variety of exoproteins that contribute to its ability to colonize
and cause disease in the host (2). The recent increase in
septic 
 
S. aureus
 
 diseases and in strains resistant to virtually all
available antibiotics puts urgency to a better understanding
of staphylococcal virulence strategies and new means to
combat 
 
S. aureus
 
 infections (3).
An immediate host response toward bacterial infection is
the migration of leukocytes from the circulation into the
sites of infection. Numerous exogenously and endoge-
nously produced leukocyte chemoattractants that initiate
leukocyte migration and activation have been identified.
They include both the “classical” chemoattractants, like
formylated peptides, C5a, C3a, platelet-activating factor
(PAF), and leukotriene B
 
4
 
, as well as the superfamily of
chemokines that selectively induce infiltration, trafficking,
and homing of leukocytes (4, 5). The effects of all of these
chemoattractants on their target cells are mediated through
specific cell surface receptors, which belong to the super-
family of seven transmembrane, heterotrimeric G protein–
coupled receptors (GPCRs; 6). Neutrophils bear several
members of this receptor family on their surface including
the receptors for formylated peptides, C5a, C3a, PAF,
and leukotriene B
 
4
 
, as well as the chemokine receptors
CXCR1 and CXCR2 that recognize IL-8 and NAP/
GRO/ENA, respectively. After activation, these receptors
are desensitized to repeated stimulation with the same or
other agonists, which is called homologous and heterologous
desensitization, respectively. Desensitization might be criti-
cal for maintaining the capacity of the cells to sense a
chemoattractant gradient (7).
Although the ability of 
 
S. aureus
 
 to escape from human
host defenses is a well-known characteristic, the underlying
mechanisms have remained unclear. Early reports suggest
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that some 
 
S. aureus
 
 strains possess an activity to delay leu-
kocyte migration toward the site of infection. In 1967,
Agarwal (8) discovered a strong strain-dependent difference
in the ability to produce a purulent lesion after subcutane-
ous injection of staphylococci in mice. Mice challenged
with “virulent” strains showed a 2-h delay in leukocyte in-
flux and accumulation of edema fluid compared with
“nonvirulent” strains. It was postulated that these virulent
strains inhibit early leukocyte migration toward the site of
infection (8). Hill (9) reported in 1968 that in contrast to
nonvirulent strains, isolated cell wall fractions of “mouse-
virulent” strains of 
 
S. aureus
 
 inhibited the accumulation of
edema fluid at the site of injection. In 1976, Russell et al.
(10) found chemotaxis-inhibiting properties for neutrophils
and monocytes of several 
 
S. aureus
 
 strains in a modified
Boyden chamber system.
These reports prompted us to look further into the pro-
posed chemotaxis-inhibiting properties of 
 
S. aureus
 
. Re-
cently, we described an extracellular component produced
by 
 
S. aureus
 
 that specifically impaired neutrophil chemo-
taxis toward fMLP, a synthetic formylated peptide, and
C5a (11). In this study, we isolated and identified this sub-
stance as a new protein, chemotaxis inhibitory protein of 
 
S.
aureus
 
 (CHIPS), which is able to specifically inhibit C5a-
and fMLP-induced responses of neutrophils and mono-
cytes. By constructing an 
 
S. aureus
 
 CHIPS knockout and
complemented strain, we show that the activity completely
matched with the presence of the CHIPS gene. CHIPS is
produced by 
 
S. aureus
 
 in vivo and is also able to reduce the
C5a-induced recruitment of neutrophils into the peritoneal
cavity in a mouse model.
 
Materials and Methods
 
Reagents.
 
fMLP and C5a were obtained from Sigma-Aldrich.
IL-8 and macrophage inflammatory protein 1
 
  
 
(MIP-1
 
 
 
)
 
 
 
were
purchased from PeproTech. Boron dipyrromethane (BODIPY)-
and FITC-labeled fMLP (BODIPY-N-formyl-Nle-Leu-Phe-
Nle-Tyr-Lys), BCECF-AM, and Fluo-3-AM were obtained
from Molecular Probes. S5/1 mAb (anti-CD88; C5aR) was pro-
vided by O. Götze (University Göttingen, Göttingen, Germany).
SE-2 (anti-CD128w; IL-8RA) and anti-PAFR mAb were from
Qbiogene. The secondary FITC-labeled goat F(ab
 
 
 
)
 
2 
 
anti–mouse
Ig was from DakoCytomation. MMK-1 peptide (LESIFRSLL-
FRVM) was synthesized by Sigma-Genosys.
 
Chromatography.
 
Chromatographic procedures were per-
formed with FPLC™ equipment from Amersham Biosciences at
4
 
 
 
C. 
 
S. aureus
 
 Newman or clinical isolate 1690 supernatant (11)
was passed over a reactive Yellow 86, a deoxyribonucleic acid
cellulose, and a Reactive Green 19 column, respectively (all from
Sigma-Aldrich), coupled in tandem. The Reactive Green column
was eluted with 2 M NaCl containing 1 mM phenylmethylsulfo-
nylfluoride. The eluate was passed over a Superdex 200 HR col-
umn (Amersham Biosciences). Fractions were screened in a flow
cytometer for inhibition of binding of BODIPY-labeled formyl-
ated peptides to neutrophils as previously described (11). Active
fractions were applied to a Mono Q HR anion exchange column
(Amersham Biosciences) in 10 mM Tris-HCl, pH 8.0, and eluted
with 0–1 M NaCl. Active fractions were analyzed on 12.5%
SDS-PAGE.
 
Receptor Expression on Human Neutrophils and Chemotaxis.
 
Human neutrophil isolation and receptor expression were per-
formed as previously described (11). In brief, human neutrophils
were incubated with increasing concentrations of CHIPS for 30
min at 37
 
 
 
C in RPMI containing 0.05% human serum albumin
(HSA; RPMI/0.05% HSA). The samples were then incubated
with 10 
 
 
 
g/ml anti-C5aR, anti–IL-8RA, anti-PAFR mAb, or 1
 
 
 
M BODIPY-labeled fMLP on ice for 30 min. After washing
twice, the neutrophils, incubated with mAbs, were incubated
with FITC-labeled goat F(ab
 
 
 
)
 
2 
 
anti–mouse Ig for 30 min on ice.
Samples were analyzed on a FACScan™ flow cytometer (Becton
Dickinson). Chemotaxis of human neutrophils toward chemoat-
tractants C5a and fMLP was determined using BCECF-labeled
neutrophils as previously described (11). In brief, neutrophils
were incubated with increasing concentrations of CHIPS for 30
min at 37
 
 
 
C in RPMI/0.05% HSA. The cells were then washed
once and resuspended in HBSS/1% HSA (2.5 
 
  
 
10
 
6 
 
c/ml). The
cells (100 
 
 
 
l) were added to the upper compartment of a Transwell
system (3 
 
 
 
m; Costar), which was placed into a 24-well plate
containing 600 
 
 
 
l HBSS/1% HSA, 10
 
 
 
7 
 
M fMLP or 10
 
 
 
10 
 
M
C5a. After 30 min of incubation at 37
 
 
 
C/5% CO
 
2
 
, the inlays
were removed and the fluorescence of the well was read in a
Cytofluor
 
II 
 
multiwell fluorometer (PerSeptive Biosystems).
 
NH
 
2
 
-terminal Sequencing.
 
For NH
 
2
 
-terminal sequencing, the
purified protein was blotted onto a polyvinylidene difluoride
membrane and stained with Coomassie brilliant blue according to
the manufacturer’s instructions (ProBlott; Applied Biosystems).
The band of interest was excised and sequenced by the Sequence
Center Utrecht.
 
DNA Sequencing.
 
Genomic DNA of 
 
S. aureus
 
 Newman was
isolated as previously described (12). A set of degenerative primers
was designed on basis of the first 32 sequenced amino acids taking
into account the codon usage of staphylococci and used to directly
sequence the genomic 
 
S. aureus
 
 Newman DNA by cycle sequenc-
ing as previously described (13). With primer 5
 
 
 
-GAAAAA-
GAAAAAGCATATAAAGAA-3
 
  
 
a sequence was obtained, which
was extended by primer walking. The program tblastn with the
nonredundant DNA database and the microbial genomes database
at http://www.ncbi.nlm.nih.gov was used to perform sequence
similarity searches. The 
 
chp
 
 sequence is available from GenBank/
EMBL/DDBJ under accession number AF 285146.
 
chp Knockout.
 
To inactivate the 
 
chp
 
 gene of 
 
S. aureus
 
 New-
man, DNA fragments of 840 bp upstream and 510 bp down-
stream of 
 
chp
 
 were amplified by PCR and cloned together with
the 
 
ermB
 
 gene from Tn551 into the temperature-sensitive shuttle
plasmid pBT2 as depicted in Fig. 2 A. After cloning in 
 
Escherichia
coli
 
 DH5
 
 
 
, the resulting plasmid pBT
 
 
 
chp was transformed into
 
S. aureus
 
 Newman to achieve integration of the 
 
ermB
 
 gene into
the genome by homologous recombination. Mutants were en-
riched by cultivation at 42
 
 
 
C in the presence of 2.5 
 
 
 
g/ml erythro-
mycin.  The proper integration of 
 
ermB
 
, which is considerably
larger than 
 
chp
 
, was confirmed by PCR analysis. A 290-bp frag-
ment encoding the mature portion of CHIPS was deleted. To
complement the knockout strain with the 
 
chp
 
 gene, plasmid
pRBchp was constructed by cloning a 1,293-bp PCR fragment
bearing the 
 
chp
 
 gene together with the putative promoter region
(738 bp noncoding upstream DNA) into the shuttle vector
pRB473. 
 
E. coli
 
– and 
 
Staphylococcus
 
-specific plasmid vectors and
molecular methods used have been described (13–16).
 
Expression of CHIPS in E. coli.
 
The 
 
chp
 
 gene, except for the
signal sequence, was amplified by PCR on chromosomal DNA
of 
 
S. aureus
 
 Newman using 
 
Pwo
 
 DNA polymerase (Roche Diag-
nostics). The PCR product was cloned into the pTrcHISB vec- 
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tor (Invitrogen) directly downstream the enterokinase cleavage
site. The vector was transformed into TOP10 
 
E. coli
 
 and recom-
binant CHIPS was expressed and purified according to the manu-
facturer’s instructions (Invitrogen).
 
Detection of chp in Clinical S. aureus Isolates.
 
PCR was per-
formed on the chromosomal DNA of 244 clinical 
 
S. aureus
 
 isolates
using the forward primer 5
 
 
 
-GAAAAAGAAATTAGCAACAA-
CAG-3
 
  
 
and the reverse primer 5
 
 
 
-CATAAGATGATTTA-
GACTCTCC-3
 
 
 
.
 
CHIPS Binding to Blood Cells.
 
To determine the binding of
CHIPS to different cell types, FITC-labeled CHIPS (CHIPS-
FITC) was used. FITC-labeling of CHIPS was performed as fol-
lows. 500 
 
 
 
g/ml CHIPS was incubated with 50 
 
 
 
g/ml FITC in
0.1 M sodium carbonate buffer, pH 9.6, for 1 h at 37
 
 
 
C. Subse-
quently, CHIPS-FITC was separated from unbound FITC using a
G25-desalting column (Amersham Biosciences). Fractions were
collected and tested for the presence of CHIPS (OD280) and
FITC (OD496) in a spectrophotometer. Fractions containing
CHIPS-FITC were pooled. Human neutrophils and mononuclear
cells were incubated with increasing concentrations of CHIPS-
FITC for 45 min on ice in the presence of PE-conjugated anti-
CD14 mAb (Becton Dickinson). Samples were analyzed on a
FACScan™ flow cytometer using scatters and anti-CD14 staining
to distinguish the different cell populations. In separate experi-
ments, CHIPS-FITC binding was tested on neutrophils of mice,
rabbits, rats, guinea pigs, pigs, and dogs. Leukocytes were isolated
from heparinized blood by either red blood cell lysis of whole
blood or standard Ficoll-Histopaque isolation as for human cells.
Specific binding of CHIPS-FITC was determined to neutrophils
identified by their characteristic scatter pattern.
 
Calcium Mobilization.
 
Calcium mobilization with isolated hu-
man neutrophils and monocytes (17) was performed as previously
described (11). In brief, Fluo-3–loaded cells were incubated with
or without 1 
 
 
 
g/ml CHIPS. Basal calcium levels were then mea-
sured in the FACSCalibur™ flow cytometer (Becton Dickinson),
after which agonist (10
 
 
 
9 
 
M fMLP, 10
 
 
 
10 
 
M C5a, 10
 
 
 
10 
 
M IL-8,
or 10
 
 
 
10 
 
M MIP-1
 
 
 
) was added. 5 min after the first stimulus, the
neutrophils were rechallenged with a second agonist. In separate
experiments, different concentrations of CHIPS were tested on
mouse and human whole blood leukocytes. Specific neutrophil
response to 10
 
 
 
10 
 
M C5a was measured by electronic gating on
scatters (human) and specific anti–mouse granulocyte mAb stain-
ing (R-PE–conjugated RB6-8C5; Caltag).
 
CHIPS Production In Vivo. S. aureus
 
 Newman or its chp dele-
tion mutant were grown overnight on a blood agar plate and
washed in PBS. C57Bl mice were challenged intraperitoneally
with 200  l (109 CFU) S. aureus Newman or its chp deletion mu-
tant. After 4 h, mice were killed, the peritoneal lavage (2.5 ml)
was collected, and the amount of CHIPS was determined with a
specific ELISA using a mAb as capture and a polyclonal rabbit
IgG as detection antibody. Recombinant CHIPS was used as the
reference standard protein. The ELISA has a limit of detection of
100 pg/ml. All animal experiments were performed in compli-
ance with University of Utrecht guidelines and were approved by
the institutional animal care and ethics committee.
Mouse Neutrophil Influx Model. 8–12-wk-old C57Bl mice
were pretreated by intravenous injection of 100  l PBS contain-
ing 0, 3, 10, or 30  g CHIPS and after 15 min they were chal-
lenged intraperitoneally with 10  g human C5a. After 3 h, mice
were killed, the peritoneal lavage was collected, and the number
of emigrated neutrophils was quantified and analyzed by flow cy-
tometry by differential staining using CyChrome-conjugated
anti–mouse CD45 (BD Biosciences) and R-PE–conjugated anti–
mouse granulocyte (RB6-8C5).
Results
Isolation of CHIPS. The chemotaxis-inhibiting com-
ponent in the supernatant of the clinical strain S. aureus
1690 (11) was purified by ligand dye chromatography, gel
Figure 1. Purified CHIPS inhibits neutrophil chemotaxis toward C5a and fMLP. (A) CHIPS was purified by ligand dye chromatography and gel filtration
from S. aureus culture supernatant. Active fractions were pooled and concentrated. SDS-PAGE revealed a band of  15 kD. The right lane represents a
marker. (B) CHIPS affects C5aR and FPR expression on neutrophils in a dose-dependent fashion. Binding of BODIPY-formylated peptide ( ) and
anti-C5aR mAb ( ) to their receptors on neutrophils is inhibited after 30 min of incubation with different concentrations of CHIPS, whereas binding of
anti-PAFR ( ) and anti–IL-8R ( ) mAb is not inhibited. Data are expressed as fluorescence values compared with neutrophils without CHIPS and are
mean   SEM of three separate experiments. (C) CHIPS inhibits chemotaxis of neutrophils toward 10 7 M fMLP ( ) and 10 10 M C5a ( ) after incubation
of neutrophils with different concentrations of CHIPS. Data are expressed as the percentage of migrated neutrophils added to the upper compartment of
the transwell chemotaxis chamber and are mean   SEM of one representative experiment (n   2–4). Migration of untreated neutrophils was 79% for
C5a and 85% for fMLP.CHIPS, a Bacterial Antiinflammatory Agent 690
permeation, and anion exchange chromatography. To de-
tect the samples containing the chemotaxis-inhibiting ac-
tivity, all samples were screened by flow cytometry for
the inhibition of binding of fluorescent-labeled formyl-
ated peptides to neutrophils. The final preparation re-
vealed a nearly homogeneous protein band of  15 kD on
SDS-PAGE (Fig. 1 A). The purified protein exhibited the
same activity as the supernatant. It inhibited binding of
formylated peptides and anti-C5aR antibodies to neutro-
phils (Fig. 1 B) as well as neutrophil chemotaxis toward
fMLP and C5a (Fig. 1 C). Neither expression of the re-
ceptors for IL-8 and PAF were affected nor their chemo-
tactic activity. The protein itself showed no direct che-
motactic activity (not shown). NH2-terminal sequencing
identified the first 32 amino acids, which showed no ma-
jor homology with any protein in databases. We named
this new protein chemotaxis inhibitory protein of S. au-
reus (CHIPS).
Identification of the CHIPS Gene. To identify the CHIPS
gene, we performed direct sequencing on genomic DNA of
S. aureus Newman, which is also a CHIPS-producing strain.
This yielded a DNA sequence encoding a protein of 149
amino acids: MKKKLATTVLALSFLTAGISTHHHSAKA-
FTFEPFPTNEEIESNKKMLEKEKAYKESFKNSGLP-
TTLGKLDERLRNYLKKGTKNSAQFEKMVILTEN-
KGYYTVYLNTPLAEDRKNVELLGKMYKTYFFKK-
GESKSSYVINGPGKTNEYAY. The NH2-terminal 28
amino acids constituted a signal peptide containing a signal
peptidase 1 cleavage site (underlined) followed by amino acids
that perfectly matched the NH2-terminal CHIPS sequence
(bold). The mature protein had a mass of 14.1 kD. The gene,
named chp, was preceded by a Shine Dalgarno sequence and
followed by three stop codons. In strain Newman chp was
found to be located on the 3  end of a bacteriophage. This
bacteriophage is incorporated in the gene for  -toxin (hlb) and
its 3  end carries, beside chp, the genes for staphylokinase (sak)
and staphylococcal enterotoxin A (sea).
CHIPS Knockout S. aureus Strain Lacks Chemotaxis-inhibit-
ing Activity. To confirm that chp was responsible for the
CHIPS activity in the S. aureus supernatant, a CHIPS
knockout strain was constructed by replacement of chp
with an erythromycin resistance cassette (Fig. 2 A). This re-
sulted in total loss of CHIPS activity and absence of the
protein in the culture supernatant (Fig. 2, B and D). When
the knockout strain was complemented with plasmid pRB-
chp, containing chp with its putative promoter region,
CHIPS activity was restored. When S. aureus COL (chp
negative by PCR) was transformed with pRBchp, it
showed CHIPS activity and produced the protein (Fig. 2,
C and D). These data show that CHIPS activity correlates
with the presence of chp. Additionally, recombinant
CHIPS produced by E. coli had exactly the same activity as
native S. aureus CHIPS (unpublished data).
Prevalence in Clinical S. aureus Isolates. To investigate the
prevalence of chp in clinical S. aureus isolates, we screened
204 methicillin-sensitive isolates (102 from blood stream in-
fections and 102 from healthy nasal carriers) and 40 methicil-
lin-resistant S. aureus strains by PCR. Of all strains, 62%
were positive for chp and the presence of chp neither corre-
lated with the clinical source of the strains nor differed be-
tween methicillin-sensitive and methicillin-resistant isolates.
CHIPS Binds to Human Neutrophils and Monocytes. To
examine the binding capacity of CHIPS to different leuko-
cytes, FITC-labeled CHIPS was used. CHIPS specifically
bound to human neutrophils and monocytes and not to
lymphocytes (Fig. 3), which indicates its specificity for those
cells that pose the greatest threat for invading staphylococci.
CHIPS Specifically Inhibits the fMLP- and C5a-induced
Calcium Mobilization. The hallmark for the GPCR is a
rapid and transient increase in free intracellular calcium
Figure 2. S. aureus Newman CHIPS knockout strain. Construction
of S. aureus Newman CHIPS knockout results in the total loss of
CHIPS activity and the CHIPS protein band in the culture supernatant.
A CHIPS knockout was constructed by homologous recombination
with plasmid pBT chp, whereby an erythromycin resistance cassette
replaced chp (A). Binding of BODIPY-labeled formylated peptide to
neutrophils after preincubation with different concentrations (vol/vol)
of supernatant of S. aureus Newman wild-type ( ), S. aureus Newman
 chp ( ), and S. aureus Newman  chp complemented with pBRchp
( ) (B) or S. aureus COL wild-type ( ) and S. aureus COL transformed
with pBRchp ( ) (C). Data are mean   SEM of three independent
experiments. Detection of CHIPS in S. aureus culture supernatants by
Western blot analysis using CHIPS-specific polyclonal rabbit antiserum.
Lanes 1 and 4 contain proteins from S. aureus Newman wild-type,
lane 2 from S. aureus Newman  chp, lane 3 from S. aureus Newman
 chp-pRBchp, lane 5 from S. aureus COL wild-type, and lane 6 from
S. aureus COL-pRBchp (D).de Haas et al. 691
upon ligand binding (6, 18). The inhibiting effect of
CHIPS on the fMLP- and C5a-induced calcium mobiliza-
tion in human neutrophils was not due to desensitization.
CHIPS specifically blocked the calcium mobilization of
neutrophils induced by fMLP or C5a, but not IL-8 (Fig. 4).
CHIPS-treated cells, triggered with fMLP or C5a, re-
sponded with a normal calcium response to a rechallenge
with IL-8 (Fig. 4, A and C). Vice versa, CHIPS-treated
cells were normally activated by IL-8, but failed to mount a
calcium mobilization upon rechallenge with fMLP or C5a
(Fig. 4, B and D). Buffer-treated cells were unaffected in
their primary response to fMLP, C5a, and IL-8, whereas
their secondary response to a heterologous stimulus was
lower due to desensitization. The full secondary response
to IL-8 of CHIPS-treated cells, preexposed to fMLP or
C5a, can be explained by the efficient FPR and C5aR re-
ceptor blockade by CHIPS. CHIPS itself did not induce a
calcium response. CHIPS also inhibited the fMLP- and
C5a-induced calcium mobilization in monocytes, whereas
the response to MIP-1  was not affected (Fig. 5). In addi-
tion, CHIPS did not inhibit human neutrophils triggered
with an FPRL1-specific agonist, the synthetic peptide
MMK-1 derived from a random peptide library that does
not activate FPR (unpublished data and 19). We conclude
that CHIPS affects specifically two members of the GPCR
family and is not toxic for cells because the cellular re-
sponse to MMK-1, IL-8, and MIP-1  remained intact.
CHIPS Is Human Specific. As chp is located on a bacte-
riophage together with the two human-specific virulence
genes,  sak and sea, we tested the species specificity of
Figure 3. CHIPS binds to phagocytes. Dose-dependent binding of
CHIPS-FITC to neutrophils ( ), monocytes ( ), and lymphocytes ( ).
Cells were identified based on scatter parameters and anti-CD14 staining.
Data are mean   SEM of five independent experiments.
Figure 4. CHIPS specifically inhibits fMLP- and C5a-induced calcium mobilization in neutrophils. The effect of CHIPS on intracellular-free calcium
release induced by 10 9 M fMLP, 10 10 M C5a, and 10 10 M IL-8 in neutrophils was determined using Fluo-3–labeled cells and flow cytometry. After
preincubating neutrophils with 1  g/ml CHIPS (gray lines) or buffer (black lines), the basal fluorescence level was measured for each sample before
fMLP (A), C5a (C), or IL-8 (B and D) was added (indicated by first arrow). To show receptor specificity, cells were rechallenged with a second stimulus
of fMLP (B), C5a (D), or IL-8 (A and C) after 5 min (indicated by second arrow).CHIPS, a Bacterial Antiinflammatory Agent 692
CHIPS. Binding of FITC-labeled CHIPS to isolated neu-
trophils of different animal species revealed a low binding
to neutrophils of all species tested when compared with
human neutrophils (Fig. 6 A). Furthermore, the efficacy of
CHIPS to inhibit the C5a-induced calcium mobilization
was evaluated with human and mouse neutrophils. CHIPS
showed a 30-fold reduced capacity to inhibit the C5a-induced
calcium mobilization in mouse neutrophils as compared
with human neutrophils (Fig. 6 B). These results suggest
that CHIPS is human specific.
CHIPS Is Produced In Vivo. CHIPS is secreted by S. au-
reus in vitro in sufficient amounts to inhibit neutrophil acti-
vation. However, to demonstrate a role for CHIPS in the
virulence of S. aureus, we examined whether S. aureus pro-
duces detectable amounts of CHIPS in vivo. Therefore,
mice were injected intraperitoneally with 109 CFU S. aureus
Newman or the CHIPS knockout strain. After 4 h, 8.18  
2.89 ng CHIPS was recovered from the peritoneal lavage of
mice injected with S. aureus Newman (n   6), whereas no
CHIPS was found in knockout strain-injected mice (n   2).
This shows that in a localized infection, S. aureus actively se-
cretes only minimal amounts of CHIPS in the surroundings.
CHIPS Inhibits the Mouse Neutrophil Influx In Vivo. To
investigate the potency of CHIPS to specifically inhibit the
neutrophil migration in vivo, mice were intravenously
treated with CHIPS and subsequently, after 15 min, intra-
peritoneally challenged with human C5a. At least 10  g of
CHIPS per mouse was needed to give a 65% inhibition of
neutrophil influx (Fig. 7). These results indicate a potential
use of CHIPS as an antiinflammatory drug in diseases
where influx of neutrophils is more detrimental than bene-
ficial for the host.
Discussion
When S. aureus invades the human host, complement is
rapidly activated, resulting in opsonization of the bacteria
and the generation of large amounts of C5a (20–22). To-
gether with formylated peptides, side products of bacterial
translation, generation of C5a constitutes the first trigger of
the innate immune system (23). These early signs of bacte-
rial invasion are recognized by the innate immune system
through two related receptors on neutrophils, the C5aR
and FPR. In vitro, in vivo, and possibly during S. aureus in-
fection, recognition by these two receptors is counteracted
by CHIPS as it inhibits specifically the C5a- and fMLP-
induced responses in neutrophils and monocytes. Moreover,
CHIPS inhibits the neutrophil recruitment toward C5a in a
Figure 5. CHIPS specifically inhibits fMLP- and C5a-induced calcium
mobilization in monocytes. The effect of CHIPS on intracellular-free
calcium release induced by 10 9 M fMLP, 10 10 M C5a, and 10 10 M
MIP-1  in monocytes was determined using Fluo-3–labeled cells and
flow cytometry. After preincubating monocytes with 1  g/ml CHIPS
(gray lines) or buffer (black lines), the basal fluorescence level was mea-
sured for each sample before fMLP (A), C5a (B), or MIP-1  (C) was
added (indicated by arrow).
Figure 6. CHIPS binding to neutrophils of different species. (A) Leu-
kocytes of different species were incubated with 1  g/ml CHIPS-FITC
and analyzed by flow cytometry based on scatter parameters to identify
neutrophils. Data shown are from one representative experiment. (B) The
effect of different concentrations CHIPS on the C5a-induced calcium
mobilization in human ( ) and mouse ( ) neutrophils. Data are expressed
as percentage inhibition of the response of control cells to 10 10 M C5a
(n   2). The response was defined by the difference in mean fluorescence
(MFL) of basal level and maximal level after challenge ( MFL   84.3 for
human and 22.9 for mouse).de Haas et al. 693
mouse peritonitis model. Because CHIPS did not inhibit
receptors for secondary chemoattractants, such as IL-8, we
hypothesize that CHIPS plays a major role early in bacterial
invasion. Once staphylococci have multiplied abundantly,
the overwhelming presence of other chemokines will over-
come CHIPS inhibitory effects causing massive influx of
neutrophils. This results in the typical hallmark of a staphy-
lococcal infection, a purulent lesion (1). As yet, it is not
known how CHIPS expression is regulated, but we would
predict from its ligand specificity that CHIPS expression is
most abundant at the onset of infection.
As CHIPS is an actively excreted protein of S. aureus, the
S. aureus–induced chemotaxis-inhibiting findings of Agar-
wal (8) might be attributed to the in vivo production of
CHIPS by the virulent S. aureus strains. The observation of
a 2-h delay in leukocyte migration toward the infected site
would correlate with our hypothesis of an early effect of
CHIPS inhibiting the leukocyte recruitment toward the
two first chemoattractants produced, formylated peptides
and C5a. Recently, extracellular adherence protein (Eap)
of S. aureus was reported to inhibit leukocyte chemotaxis
by its interaction with intercellular adhesion molecule 1
(24). Like CHIPS, Eap was produced by S. aureus Newman
in vivo, which suggests that this strain has at least two dif-
ferent mechanisms to avoid leukocyte recruitment (25).
Given its potent action on human phagocytes, CHIPS
may represent an important virulence factor. This seems to
be in agreement with the abundance of chp (62%) in S. au-
reus isolates. The presence of chp did not correlate with the
development of bactereamia. There are two different expla-
nations for this. We hypothesize that CHIPS is mainly im-
portant in the initial interaction with the host and mainly
contributes to effective colonization or early stages of infec-
tion. In addition, there might be some redundancy in viru-
lence factors, such as Eap, which avoid the innate immune
system. Once the bacterium harbors more than a threshold
number of these factors, the bacterium becomes pathogenic.
This research includes CHIPS as one of these factors.
The human specificity of CHIPS as shown by a 30-fold
difference in activity toward human cells as compared with
mouse cells, in combination with its low in vivo expres-
sion, hampers testing of CHIPS in a mouse infection model
or other animal models. Apart from chp, the other adjacent
genes sak and sea have also been reported to be highly hu-
man specific. The response of mouse T cells to the super-
antigen staphylococcal enterotoxin A requires 1,000-fold
higher concentrations compared with human T cells (26).
In addition, the ability of bacterial plasminogen activators
to cleave different animal plasminogen is restricted. Staphy-
lokinase could only activate plasminogen of humans, dogs,
and baboons (27). The exact role of CHIPS in S. aureus
virulence will be a subject for future studies. As an in vivo
infection model was not possible due to the human speci-
ficity of CHIPS, we included a mouse peritonitis model
with purified CHIPS. As we could simply overdose CHIPS
in this model, we were able to show a proof of principle for
the in vivo anti-chemotactic action of CHIPS.
CHIPS fulfils a unique function, affecting two related re-
ceptors with strikingly different ligand specificities. Both
the C5aR and FPR belong to the superfamily of seven
transmembrane, heterotrimeric GPCRs (28, 29). All mem-
bers of this family have a comparable architecture and show
a 20–30% amino acid homology, mainly in the transmem-
brane regions, whereas the ligands are highly diverse and
receptor specific. Small molecules, such as fMLP, bind to
their GPCR in the interhelical region, whereas larger mol-
ecules, such as C5a, use a two-site motif for binding their
GPCR (30, 31).
How CHIPS interferes with both fMLP and C5a re-
sponses is still speculative. It is unlikely that CHIPS affects
common downstream signaling events related to the
GPCR as was shown for pertussis toxin (32), because the
MMK-1, IL-8, and MIP-1   responses were unaffected.
Binding of CHIPS-FITC was restricted to phagocytes, in
which neutrophils showed a twofold higher binding than
monocytes. This coincides with the expression of the
C5aR and FPR on the respective cell types (33–36) and
could therefore implicate direct binding to these chemo-
kine receptors. The fact that CHIPS binds to phagocytes
implies that CHIPS probably is not a protease-like protein
cleaving (a part of) the receptor, as was described for other
receptors (37, 38). Alternative explanations, in which
CHIPS could act via a separate CHIPS receptor or inter-
feres with proper surface exposure of C5aR and FPR by
mimicking conserved receptor transmembrane regions
(39), do not provide a plausible explanation for its narrow
specificity for C5aR and FPR. The exact mechanism of
CHIPS inhibiting fMLP- and C5a-induced responses will
be further investigated.
Figure 7. CHIPS inhibits the C5a-induced neutrophil migration in
vivo. Mice were pretreated by intravenous injection of different concen-
trations of CHIPS and after 15 min were challenged intraperitoneally
with human C5a. After 3 h, the percentage of neutrophils in the perito-
neal lavage was analyzed. Data are expressed as percentage inhibition
compared with buffer-treated mice challenged with C5a after correction
for control nontreated mice. Data are mean   SEM of two to three separate
experiments (n   2 mice per treatment).CHIPS, a Bacterial Antiinflammatory Agent 694
We present data that implicate a new virulence strategy
of S. aureus and thereby a new potential target in the treat-
ment of S. aureus infection. In addition, the potent capacity
of CHIPS to inhibit neutrophil chemotaxis, in vitro and in
vivo, makes this new protein a promising candidate antiin-
flammatory drug for those diseases in which C5a-induced
damage by neutrophils plays a pivotal role (40–44).
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